-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q4 2020 to Q3 2024.
- Inhibikase Therapeutics, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 100M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)